ADJUVANT CAPITAL, LP
ADJUVANT CAPITAL, LP is a Seed, Series A and Series B fund in the US, Europe, low-income-countries and middle-income-countries writing $10M–$25M checks into Healthcare, life-science, global-health, infectious-diseases, maternal-child-health, nutrition, reproductive-health, sexual-health and life-sciences.
- Stages
- Seed, Series A, Series B
- Sectors
- Healthcare, life-science, global-health, infectious-diseases, maternal-child-health, nutrition, reproductive-health, sexual-health, life-sciences
- Check size
- $10M–$25M
- Invests in
- US-wide, Europe, low-income-countries, middle-income-countries
- Round role
- Leads rounds
- Actively investing
- Yes
- Founded
- 2018
- Assets under management
- $300M
- Website
- adjuvantcapital.com
Thesis
Adjuvant Capital, a venture capital firm founded in 2018, focuses on life science technologies addressing critical global public health issues such as infectious diseases, maternal and child health, nutrition, and reproductive/sexual health. They seek companies with demonstrated human safety and efficacy, typically in Phase II or later clinical trials, requiring strong proof-of-concept data. Their investment strategy targets Seed, Series A, and Series B stages, with a geographic focus on North America and Europe, and a significant emphasis on low- and middle-income countries. Adjuvant Capital typically invests $10 million to $25 million per deal, utilizing preferred equity to accelerate the global availability of impactful medical innovations. The firm manages a $300 million fund and aims for both financial returns and measurable social impact.
Common questions
Does ADJUVANT CAPITAL, LP invest at the Seed stage?
Yes. ADJUVANT CAPITAL, LP lists Seed, Series A and Series B among the stages it invests in.
What check size does ADJUVANT CAPITAL, LP write?
ADJUVANT CAPITAL, LP writes $10M–$25M checks.
Where does ADJUVANT CAPITAL, LP invest?
ADJUVANT CAPITAL, LP invests in the US, Europe, low-income-countries and middle-income-countries.